The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
MeSH Review

Toxicodendron

 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Toxicodendron

 

Psychiatry related information on Toxicodendron

  • METHOD: We assessed rash incidence in 100 patients with DSM-IV bipolar disorder instructed, for their first 3 months taking lamotrigine, to avoid other new medicines and new foods, cosmetics, conditioners, deodorants, detergents, and fabric softeners, as well as sunburn and exposure to poison ivy/oak [6].
 

High impact information on Toxicodendron

 

Chemical compound and disease context of Toxicodendron

 

Biological context of Toxicodendron

 

Anatomical context of Toxicodendron

 

Associations of Toxicodendron with chemical compounds

 

Gene context of Toxicodendron

 

Analytical, diagnostic and therapeutic context of Toxicodendron

References

  1. In vitro studies of poison oak immunity. I. In vitro reaction of human lymphocytes to urushiol. Byers, V.S., Epstein, W.L., Castagnoli, N., Baer, H. J. Clin. Invest. (1979) [Pubmed]
  2. Urushiol (poison ivy)-triggered suppressor T cell clone generated from peripheral blood. Kalish, R.S., Morimoto, C. J. Clin. Invest. (1988) [Pubmed]
  3. Keratinocyte intercellular adhesion molecule-1 (ICAM-1) expression precedes dermal T lymphocytic infiltration in allergic contact dermatitis (Rhus dermatitis). Griffiths, C.E., Nickoloff, B.J. Am. J. Pathol. (1989) [Pubmed]
  4. Regulation of murine contact sensitivity to urushiol components by serum factors. Dunn, I.S., Liberato, D.J., Stampf, J.L., Castagnoli, N., Byers, V.S. J. Invest. Dermatol. (1987) [Pubmed]
  5. Suppression of urushiol-induced delayed-type hypersensitivity responses in mice with serum IgG immunoglobulin from human hyposensitized donors. Stampf, J.L., Castagnoli, N., Epstein, W., Baldwin, R.W., Byers, V. J. Invest. Dermatol. (1990) [Pubmed]
  6. Dermatology precautions and slower titration yield low incidence of lamotrigine treatment-emergent rash. Ketter, T.A., Wang, P.W., Chandler, R.A., Alarcon, A.M., Becker, O.V., Nowakowska, C., O'Keeffe, C.M., Schumacher, M.R. The Journal of clinical psychiatry. (2005) [Pubmed]
  7. Failure of a tapering dose of oral methylprednisolone to treat reactions to poison ivy. Ives, T.J., Tepper, R.S. JAMA (1991) [Pubmed]
  8. Processing of urushiol (poison ivy) hapten by both endogenous and exogenous pathways for presentation to T cells in vitro. Kalish, R.S., Wood, J.A., LaPorte, A. J. Clin. Invest. (1994) [Pubmed]
  9. Synergy between phorbol esters, 1-oleyl-2-acetylglycerol, urushiol, and calcium ionophore in eliciting aggregation of marine sponge cells. Weissmann, G., Azaroff, L., Davidson, S., Dunham, P. Proc. Natl. Acad. Sci. U.S.A. (1986) [Pubmed]
  10. Modulation of fatty acid oxidation alters contact hypersensitivity to urushiols: role of aliphatic chain beta-oxidation in processing and activation of urushiols. Kalergis, A.M., López, C.B., Becker, M.I., Díaz, M.I., Sein, J., Garbarino, J.A., De Ioannes, A.E. J. Invest. Dermatol. (1997) [Pubmed]
  11. Dose-response relationship of topically applied methylprednisolone aceponate (MPA) in healthy volunteers. Kecskés, A., Jahn, P., Wendt, H., Lange, L., Kuhlmann, R.K. Eur. J. Clin. Pharmacol. (1992) [Pubmed]
  12. Evaluation of delayed hypersensitivity: from PPD to poison ivy. Rosenstreich, D.L. Allergy proceedings : the official journal of regional and state allergy societies. (1993) [Pubmed]
  13. Quantitation and cloning of human urushiol specific peripheral blood T-cells: isolation of urushiol triggered suppressor T-cells. Kalish, R.S., Morimoto, C. J. Invest. Dermatol. (1989) [Pubmed]
  14. The role of adhesion molecules, chemotactic factors, and cytokines in inflammatory and neoplastic skin disease--1990 update. Nickoloff, B.J., Griffiths, C.E., Barker, J.N. J. Invest. Dermatol. (1990) [Pubmed]
  15. Topical immune modulation (TIM): a novel approach to the immunotherapy of systemic disease. Stricker, R.B., Goldberg, B., Epstein, W.L. Immunol. Lett. (1997) [Pubmed]
  16. Liposomes containing 3-n-pentadecylcatechol induce tolerance to toxicodendron. Colby, S.L., Artis, W.M., Rietschel, R.L. J. Invest. Dermatol. (1983) [Pubmed]
  17. Perfluorinated analogues of poison ivy allergens. Synthesis and skin tolerogenic activity in mice. Fraginals, R., Schaeffer, M., Stampf, J.L., Benezra, C. J. Med. Chem. (1991) [Pubmed]
  18. Double-headed haptens with pyrocatechol (poison ivy like) and methylene lactone functional groups: a search for skin-tolerance inducers. Mattes, H., Benezra, C. J. Med. Chem. (1987) [Pubmed]
  19. Saturated analogues of poison ivy allergens. Synthesis of trans,trans- and cis,trans-3-alkyl-1,2-cyclohexanediols and sensitizing properties in allergic contact dermatitis. Lepoittevin, J.P., Benezra, C. J. Med. Chem. (1986) [Pubmed]
  20. Keratinocyte interleukin-10 expression is upregulated in tape-stripped skin, poison ivy dermatitis, and Sezary syndrome, but not in psoriatic plaques. Nickoloff, B.J., Fivenson, D.P., Kunkel, S.L., Strieter, R.M., Turka, L.A. Clin. Immunol. Immunopathol. (1994) [Pubmed]
  21. In situ changes in the relative abundance of human epidermal cytokine messenger RNA levels following exposure to the poison ivy/oak contact allergen urushiol. Boehm, K.D., Yun, J.K., Strohl, K.P., Trefzer, U., Häffner, A., Elmets, C.A. Exp. Dermatol. (1996) [Pubmed]
  22. The poison ivy picker of Pennypack Park: the continuing saga of poison ivy. Epstein, W.L. J. Invest. Dermatol. (1987) [Pubmed]
  23. Detection of telomerase activity in malignant and nonmalignant skin conditions. Taylor, R.S., Ramirez, R.D., Ogoshi, M., Chaffins, M., Piatyszek, M.A., Shay, J.W. J. Invest. Dermatol. (1996) [Pubmed]
  24. Induction of suppressor T cells for lymph node cell proliferation after contact sensitization of mice with a poison oak urushiol component. Dunn, I.S., Liberato, D.J., Castagnoli, N., Byers, V.S. Immunology (1984) [Pubmed]
  25. Preservation of allergic contact dermatitis to poison ivy (urushiol) in late HIV disease. The implications and relevance to immunotherapy with contact allergens. Smith, K.J., Skelton, H.G., Nelson, A., Wagner, K.F., Hackley, B.E. Dermatology (Basel) (1997) [Pubmed]
 
WikiGenes - Universities